Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Patatin-like phospholipase domain containing-3 Ile148Met and fibrosis progression after liver transplantation.

Valenti L, Fargion S.

Hepatology. 2011 Oct;54(4):1484. doi: 10.1002/hep.24601. No abstract available.

PMID:
21837747
2.

The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C.

do O NT, Eurich D, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE.

Hepatology. 2011 Oct;54(4):1483-4. doi: 10.1002/hep.24535. Epub 2011 Aug 19. No abstract available.

PMID:
21748761
3.

Raised sympathetic activity and blood ammonia could increase sensitivity to infections in patients with cirrhosis and refractory ascites who are using beta-blockers.

Kalambokis GN, Tsianos EV.

Hepatology. 2011 Oct;54(4):1486-7. doi: 10.1002/hep.24439. Epub 2011 Jul 21. No abstract available.

PMID:
21608005
4.

PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function?

Dubuquoy C, Burnol AF, Moldes M.

Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):30-5. doi: 10.1016/j.clinre.2012.06.014. Epub 2012 Aug 11.

PMID:
22884299
5.

First European Young Hepatologist Workshop: topics and advances.

Serfaty L, Castera L, Marcellin P.

Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S1-2. doi: 10.1016/S2210-7401(11)70001-8. No abstract available.

PMID:
21742295
6.

Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation.

López-Labrador FX, Bracho MA, Berenguer M, Coscollà M, Rayón JM, Prieto M, Carrasco D, Gómez MD, Moya A, González-Candelas F.

J Viral Hepat. 2006 Feb;13(2):104-15.

PMID:
16436128
7.

Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.

Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS.

Transplantation. 2011 Aug 27;92(4):453-60. doi: 10.1097/TP.0b013e3182259282.

PMID:
21799468
8.

The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.

Selzner N, Girgrah N, Lilly L, Guindi M, Selzner M, Therapondos G, Adeyi O, McGilvray I, Cattral M, Greig PD, Grant D, Levy G, Renner EL.

Liver Transpl. 2008 Dec;14(12):1778-86. doi: 10.1002/lt.21598.

9.

Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression.

Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V.

Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):445-58. doi: 10.1586/egh.10.39. Review.

PMID:
20678018
10.

Human leukocyte antigen DR markers as predictors of progression to liver transplantation in patients with chronic hepatitis C.

Brandhagen DJ, Gross JB Jr, Poterucha JJ, Germer JJ, Czaja AJ, Smith CI, Ribeiro AC, Guerrero RB, Therneau TM, Schiff E, Gordon FD, Wiesner RH, Persing DH.

Am J Gastroenterol. 2000 Aug;95(8):2056-60.

PMID:
10950057
11.

Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma.

Corradini SG, Burza MA, Molinaro A, Romeo S.

Hepatology. 2011 May;53(5):1776; author reply 1777. doi: 10.1002/hep.24244. No abstract available.

PMID:
21351112
12.

Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.

Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, Gadba R, Tambur AR, Tur-Kaspa R, Mor E.

Cytokine. 2004 Jul 7;27(1):7-14.

PMID:
15207246
13.

Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation.

Ben-Ari Z, Tambur AR, Pappo O, Sulkes J, Pravica V, Hutchinson I, Klein T, Tur-Kaspa R, Mor E.

Transplantation. 2006 Feb 15;81(3):392-7.

PMID:
16477226
14.
15.

Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C.

Cisneros L, Londoño MC, Blasco C, Bataller R, Miquel R, Bruguera M, Ginès P, Rimola A.

Liver Transpl. 2007 Jul;13(7):1017-27.

16.

Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation.

Cotler SJ, Gaur LK, Gretch DR, Wile M, Strong DM, Bronner MP, Carithers RL Jr, Emond MJ, Perkins JD, Nelson KA.

Tissue Antigens. 1998 Nov;52(5):435-43.

PMID:
9864033
17.

Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States.

Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB.

Dig Liver Dis. 2011 Jan;43(1):66-72. doi: 10.1016/j.dld.2010.05.006. Epub 2010 Jun 17.

PMID:
20739252
18.

Examination of claudin-1 expression in patients undergoing liver transplantation owing to hepatitis C virus cirrhosis.

Zadori G, Gelley F, Torzsok P, Sárváry E, Doros A, Deak AP, Nagy P, Schaff Z, Kiss A, Nemes B.

Transplant Proc. 2011 May;43(4):1267-71. doi: 10.1016/j.transproceed.2011.03.066.

PMID:
21620107
19.

Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.

de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM, Torelli R, Cardillo M, Scalamogna M, Poli F.

Liver Transpl. 2009 Apr;15(4):390-9. doi: 10.1002/lt.21673.

20.

Genomic medicine reaches HCV-related liver transplantation: hopes and clinical and public health implications.

López-Labrador FX, Berenguer M.

J Hepatol. 2011 Aug;55(2):270-2. doi: 10.1016/j.jhep.2011.01.013. Epub 2011 Jan 31. No abstract available.

Supplemental Content

Support Center